Ignaz Semmelweis spent years trying to tell the medical establishment that doctors were killing their patients by moving from the autopsy table to the delivery room without washing their hands. The evidence he had accumulated was not ambiguous and the mortality rate in the maternity ward staffed by physicians was several times higher than the one staffed by midwives, who did not spend their mornings handling cadavers. Semmelweis identified the cause, implemented a solution and watched the death rate in his ward drop to nearly zero. The medical establishment responded by refusing to accept that physicians could be the vector of disease, by undermining his work and by eventually having him committed to a mental asylum, where he died of sepsis at forty-seven, possibly from the kind of infection he had spent his career trying to prevent. The germ theory of disease was not formally established until decades later, when Pasteur and Lister received the credit.

This story tends to be told as an aberration, as the kind of thing that happened before medicine became properly scientific, before the institutional frameworks were robust enough to absorb a challenging idea without destroying the person carrying it. It is told less often as a story about what medicine does structurally when a cause implicates the system itself, when the answer to why people are getting sick points not to an external pathogen but to a practice, an assumption, or a social arrangement that the institution would find inconvenient to examine. The distance between Semmelweis's Vienna and the present is considerable in some respects and thankfully, rather shorter in others.

The syndrome is one of the places where that distance collapses. A syndrome, in clinical language, is a collection of symptoms that tend to occur together and have been given a name, which is a useful descriptive act when the underlying cause is unknown and harmful to wait for, and a considerably less useful act when the naming substitutes for the investigation that might actually find the cause. The International Classification of Diseases contains hundreds of named syndromes. Some of them represent genuine holding categories for conditions whose mechanisms are not yet understood. Others have functioned, in practice, as a way of discharging the clinical obligation to explain what is happening to a patient by giving what is happening a name, which feels like an explanation without being one, and which tends to reduce the institutional pressure to keep looking.

Irritable Bowel Syndrome is one of the more illuminating examples because it is both extremely common and almost definitionally uninformative as a diagnosis. It describes a pattern of gastrointestinal symptoms, bloating, cramping, altered bowel habit, abdominal pain, that are real, often debilitating, and that the diagnosis of IBS does essentially nothing to explain. The symptoms ARE the diagnosis. A patient leaves the consultation with a named condition that is identical in content to the symptoms she arrived with, plus typically a recommendation for dietary modification and, depending on the presentation, a prescription for something that addresses the symptom rather than whatever is producing it. What is not routinely investigated with any systematic rigour is the question of why the gut is behaving this way, a question that, when pursued, tends to lead into territory that a standard clinical appointment is not structured to explore: the history of antibiotic use, the composition of the gut microbiome, the pattern of food intolerances that produce inflammatory responses over time rather than the immediate and visible reaction of a true allergy and are therefore considerably harder to identify, the relationship between hormonal fluctuation and gut motility, the role of chronic stress in intestinal permeability. These are not fringe hypotheses. Areas of active research with substantial published evidence exist behind them. They are also areas that require more time, more investigation and more willingness to sit with uncertainty than the syndrome framework encourages.

PCOS, Polycystic Ovary Syndrome, follows a similar pattern at a scale that makes the stakes considerably higher. It affects somewhere between eight and thirteen percent of women of reproductive age globally, making it one of the most common endocrine disorders in existence, and the clinical conversation around it has spent decades teaching patients a particular kind of resignation. You have PCOS. Here are the symptoms it produces. Here are the medications that address those symptoms. The question of what produces the condition itself, what combination of genetic predisposition, insulin resistance, endocrine disruption, inflammatory burden and environmental factors converges to create the hormonal pattern that gets labelled PCOS, receives considerably less systematic attention in most clinical encounters than the management of its downstream effects. Patients are counselled about fertility implications, about weight management, about the elevated risk of type two diabetes and cardiovascular disease. The possibility that the condition is in some meaningful sense a response to something, a signal from an endocrine system under sustained pressure, rather than simply a malfunction to be managed, is not the dominant frame in which most PCOS patients are receiving their care.

Traditional medical systems across the world have tended to approach this kind of question differently, not because they are more sophisticated in every respect, but because their foundational assumptions about the relationship between symptom and cause are structured differently. Ayurvedic medicine does not have a direct equivalent of the syndrome as a diagnostic category because its diagnostic logic begins from constitution, from the particular combination of qualities the individual body tends toward, and works outward from there to understand why a given symptom is presenting in this person at this time under these conditions. Chinese medicine's approach to what Western medicine would call IBS involves an assessment of the whole system, of digestion in relation to stress, sleep, emotional state and seasonal context, that produces a diagnosis specific to the individual rather than a category applicable to anyone presenting with the same cluster of symptoms. Neither of these systems is without its limitations, and neither is being proposed here as a replacement for evidence-based medicine in its entirety. What they represent is a different orientation toward causation, one that treats the symptom as a question rather than an answer, and that question-orientation is not absent from Western medical thinking but tends to get structurally deprioritised by an institutional framework built around the appointment, the prescription, and the ICD code.

The pharmaceutical economy is relevant here in ways that the clinical literature tends not to foreground. A cause, once identified, can often be addressed without a drug, or with a drug taken for a finite period while the underlying condition is resolved. A syndrome, by contrast, is a permanent diagnostic identity that typically requires permanent management, and permanent management is a considerably more reliable commercial proposition than a cure. This is not a conspiracy. It is a structural incentive that operates through the ordinary mechanisms of research funding, publication priority and clinical guideline development, all of which are influenced by the interests of the companies that have the most to gain from a treatment-oriented rather than a cause-oriented model of medicine. Semmelweis's problem was that his solution cost nothing and implicated the institution. The pharmaceutical industry's solutions cost considerably more and implicate nothing except the patient's biochemistry.

The question of what gets implicated when cause is actually pursued is where the medicine becomes most uncomfortable and where the syndrome framework becomes most useful as a way of not going there. Sudden Infant Death Syndrome sits at this end of the spectrum. It is defined, explicitly, as the sudden death of an infant under one year of age that remains unexplained after a thorough investigation, which means the diagnosis is by definition the absence of a cause, a label applied precisely because the cause has not been found. The research literature on risk factors for SIDS is extensive and includes prone sleeping position, overheating, bed-sharing, premature birth, and parental smoking, all of which are discussed with appropriate clinical frankness. The relationship between parental substance use and the specific pattern of arousal deficit that appears in many SIDS cases is discussed in the literature but occupies a considerably more careful register in public health communication, partly for reasons of sensitivity and partly because parental substance use is a social and economic condition with causes of its own that medicine is even less structurally equipped to address than it is to address gut permeability. The rates of what gets classified as SIDS vary substantially across countries and populations in ways that correlate with social conditions, with community structures, with the presence or absence of extended family networks in which the care of an infant is distributed across multiple alert adults rather than concentrated in one or two exhausted parents, one of whom may have been conditioned by the particular arrangements of the nuclear family and contemporary working life to be less present in the night hours than the other. These correlations are noted in the epidemiological literature. They do not typically make it into the clinical framework through which SIDS is communicated to the families it affects, because the syndrome category closes the diagnostic loop before the social question is opened.

Chronic fatigue syndrome spent decades being dismissed by the medical establishment not because the symptoms were not real but because the symptoms were not explained, and unexplained symptoms in a diagnostic culture built around identifiable pathology tend to accumulate a social interpretation in the absence of a biological one. Patients with chronic fatigue were told, in significant numbers and for a significant period, that their condition was psychosomatic, that it was a form of depression being expressed somatically, that the appropriate intervention was cognitive behavioural therapy and graded exercise, neither of which addressed whatever was actually happening and the second of which made many patients considerably worse. The research that eventually began to establish biological underpinnings, including dysfunction in energy metabolism at the cellular level, immune system abnormalities, and autonomic nervous system disruption, arrived decades after the patients had been living with both the condition and the medical establishment's scepticism about it. The delay was not purely a function of scientific difficulty. It was also a function of what the medical system found more plausible, which was a psychosocial explanation that required no new biology, over a biological explanation that would have required acknowledging that a large number of patients had been mismanaged for a long time.

Western medicine appropriated extensively from the traditions it later declined to credit. Aspirin derives from willow bark preparations used across multiple indigenous traditions for millennia. Digitalis, the foundation of a class of cardiac medications, comes from the foxglove plant used in Welsh folk medicine. Quinine came from the Cinchona bark used by Quechua people in Peru. The ethnobotanical knowledge that underlies a significant portion of the modern pharmacopoeia was collected, in many cases, by colonial-era naturalists and physicians who documented what indigenous healers were using without the healers' consent and without any subsequent acknowledgment in the patent systems that profited from the knowledge. This history is not peripheral to the question of why Western medicine has been slow to take seriously the causal frameworks of Ayurvedic or Chinese or African traditional medicine. The dismissal is not epistemically neutral. It is the continuation, in a different register, of the same relationship to indigenous knowledge that produced the original appropriation.

The patient who leaves a consultation with a syndrome diagnosis has received something real, a name, a category, membership in a community of others with the same label, and in some cases access to treatments that genuinely help with the symptoms. What she has not received is an answer to the question her body was asking, and the institution that gave her the syndrome has, in most cases, moved on to the next appointment. The cause is still in the room. It tends to stay there.

Culture is the living argument a people has with itself across time. return. enters that argument as a reader, not a referee.